Glenmark Q3 profit rises 16% on strong India, US performance

Glenmark Pharmaceuticals posted 16% growth in December-quarter profit on strong India formulations demand, improved North America performance and margin expansion, with EBITDA surging 45% and regulatory clearance enabling manufacturing restart at its US facility.

SAIL Q3 profit at Rs 374 crore on higher volumes, leverage

SAIL reported a sharp rise in December-quarter profit to Rs 374 crore, driven by higher volumes, operating leverage and disciplined cost control, despite volatile input costs and competitive pricing, while total income also rose strongly year-on-year.